logo-loader
viewIndivior PLC

Indivior long-acting drug for opioid addiction builds on early promise

Researchers confirmed that users of Sublocade reported better health, higher medication satisfaction, increased employment and decreased healthcare utilisation compared with those using a placebo with no medicinal benefit

Indivior PLC -

Indivior PLC (LON:INDV) said the injected, extended release version of its drug for opioid addiction has built on its early promise with results from a 12-month trial mirroring the findings at the six-month stage.

Researchers confirmed that users of Sublocade reported better health, higher medication satisfaction, increased employment and decreased healthcare utilisation compared with those using a placebo with no medicinal benefit.

The treatment, also known as buprenorphine, is being touted by Indivior as a long-term replacement for its best-selling addiction medication, Suboxone, which is now subject to competition after coming off patent.

"These results showed that patients experienced improvements in physical and mental health which may help in the recovery journey and positively impact lifestyle, including employment," said the study’s lead author, Walter Ling, Research Professor at the David Geffen School of Medicine, UCLA.

The team’s findings from the 12-month follow-up of the extended release treatment were published in the Journal of Substance Abuse Treatment.

The US Supreme Court earlier this year cleared the way for market access to cheaper alternatives to Indivior’s Suboxone film, which was responsible for most of the company's revenues.

While the sales erosion from generic competition hasn’t been as precipitous as first feared, Indvior has been looking usher in superior products so it can rebuild its market share.

 

Quick facts: Indivior PLC

Price: 91 GBX

LSE:INDV
Market: LSE
Market Cap: £666.52 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Electric vehicle sales to accelerate following coronavirus pandemic

Roskill analyst Jose Lazuen tells Proactive London's Andrew Scott severe falls were expected in EV sales but that European and Chinese policies coupled with consumer preferences have shown them to remain strong. He adds that policy is going to favour and push EV sales in certain jurisdictions...

1 day ago

2 min read